JP2013506675A5 - - Google Patents

Download PDF

Info

Publication number
JP2013506675A5
JP2013506675A5 JP2012532248A JP2012532248A JP2013506675A5 JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5 JP 2012532248 A JP2012532248 A JP 2012532248A JP 2012532248 A JP2012532248 A JP 2012532248A JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5
Authority
JP
Japan
Prior art keywords
antibody
notch3
notch1
antagonist
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012532248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506675A (ja
JP6025563B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/050610 external-priority patent/WO2011041336A2/en
Publication of JP2013506675A publication Critical patent/JP2013506675A/ja
Publication of JP2013506675A5 publication Critical patent/JP2013506675A5/ja
Application granted granted Critical
Publication of JP6025563B2 publication Critical patent/JP6025563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012532248A 2009-09-30 2010-09-29 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性癌の治療 Active JP6025563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30
US61/247,298 2009-09-30
PCT/US2010/050610 WO2011041336A2 (en) 2009-09-30 2010-09-29 Methods of treating cancer using notch antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015011573A Division JP2015145362A (ja) 2009-09-30 2015-01-23 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療
JP2016138236A Division JP2017014219A (ja) 2009-09-30 2016-07-13 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療

Publications (3)

Publication Number Publication Date
JP2013506675A JP2013506675A (ja) 2013-02-28
JP2013506675A5 true JP2013506675A5 (enExample) 2013-10-17
JP6025563B2 JP6025563B2 (ja) 2016-11-16

Family

ID=43127684

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012532248A Active JP6025563B2 (ja) 2009-09-30 2010-09-29 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性癌の治療
JP2015011573A Withdrawn JP2015145362A (ja) 2009-09-30 2015-01-23 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療
JP2016138236A Pending JP2017014219A (ja) 2009-09-30 2016-07-13 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015011573A Withdrawn JP2015145362A (ja) 2009-09-30 2015-01-23 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療
JP2016138236A Pending JP2017014219A (ja) 2009-09-30 2016-07-13 Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療

Country Status (21)

Country Link
US (1) US9200071B2 (enExample)
EP (1) EP2483311B1 (enExample)
JP (3) JP6025563B2 (enExample)
KR (1) KR101782180B1 (enExample)
CN (1) CN102630229B (enExample)
AU (1) AU2010300747A1 (enExample)
BR (1) BR112012007252A2 (enExample)
CA (1) CA2775880A1 (enExample)
CL (1) CL2012000800A1 (enExample)
CO (1) CO6531430A2 (enExample)
CR (1) CR20120213A (enExample)
EC (1) ECSP12011858A (enExample)
ES (1) ES2580229T3 (enExample)
IL (1) IL218662A0 (enExample)
MA (1) MA33973B1 (enExample)
MX (1) MX342250B (enExample)
PE (1) PE20120998A1 (enExample)
PH (1) PH12012500574A1 (enExample)
RU (1) RU2012117619A (enExample)
WO (1) WO2011041336A2 (enExample)
ZA (1) ZA201201984B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2133796C1 (ru) * 1997-10-09 1999-07-27 ОАО "Томский электромеханический завод им.В.В.Вахрушева" Люк смотрового колодца
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CA2765989C (en) 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies
CN105884896A (zh) 2010-12-15 2016-08-24 惠氏有限责任公司 抗缺刻蛋白1抗体
TWI589590B (zh) 2012-11-07 2017-07-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
EP2935330B1 (en) * 2012-12-19 2019-04-24 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
JP2016514130A (ja) * 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
CA2900969A1 (en) * 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
US9518121B2 (en) 2014-02-12 2016-12-13 Genentech, Inc. Anti-Jagged1 antibodies and methods of use
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
ES2931955T3 (es) 2016-04-29 2023-01-05 Aveo Pharmaceuticals Inc Anticuerpo anti-Notch3
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
JP5478254B2 (ja) 2006-10-19 2014-04-23 ジェネンテック， インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
CL2007002989A1 (es) * 2006-10-19 2008-05-16 Genentech Inc Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
JP5386364B2 (ja) * 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
CA2676008A1 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2010520280A (ja) * 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN102316897B (zh) * 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
CA2765989C (en) * 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies

Similar Documents

Publication Publication Date Title
JP2013506675A5 (enExample)
RU2012117619A (ru) ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
RU2018108048A (ru) Новые анти-pd-1 антитела
EA033072B1 (ru) Применение антител к семафорину 4d для лечения болезни хантингтона
JP2014512809A5 (enExample)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ712765A (en) Antibodies that bind csf1r
WO2014037588A3 (en) Methods and compounds for preventing, treating and diagnosing an inflammatory condition
RU2014147867A (ru) Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2017535257A5 (enExample)
JP2014205674A5 (enExample)
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
JP2013542194A5 (enExample)
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
JP2013538057A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2014526898A5 (enExample)
JP2015511962A5 (enExample)
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1